Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SYNERGY-OUTCOMES: Retatrutide and Tirzepatide in MASLD
NCT07165028Phase 3Recruiting
- Sponsor
- Eli Lilly and Company
- Start
- Oct 2025
- Primary completion
- Aug 2030
- Modality
- Peptides, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 34
01
Overview
A Phase 3 trial of retatrutide, tirzepatide in metabolic dysfunction-associated steatotic liver disease (MASLD), sponsored by Eli Lilly and Company. Started Oct 2025; status: recruiting.
02
Drugs
03
Conditions
metabolic dysfunction-associated steatotic liver disease (MASLD)
Beyond the preview
Go deeper on NCT07165028.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07165028.